DelSiTech and Tolmar Announce Global License and Development Agreement
- Tolmar secures global license to DelSiTech’s Silica Matrix technology to develop and commercialize two undisclosed drug targets
- DelSiTech and Tolmar to expand development of additional drug products across a range of therapeutic areas
- DelSiTech is eligible to receive upfront payments, development and commercial milestone payments, and royalties on licensed products
Turku, Finland and Dublin, Ireland – 13th February 2024. Clinical-stage drug delivery and development company, DelSiTech Ltd., and Tolmar International Ltd., a fully-integrated pharmaceutical company, today announce the signing of a global license and development agreement, further strengthening their collaboration, following investment from Tolmar in January 2024.
